Results 31 to 40 of about 3,959 (186)
Frontiers in Tropical Diseases, 2023 The repurposing of approved drugs is an appealing method to fast-track the development of novel therapies for neglected diseases. Amiodarone and dronedarone, two approved antiarrhythmic agents, have been reported to have potential for the management of ...
Amanda F. Francisco +16 more
doaj +1 more source
Quinol derivatives as potential trypanocidal agents.
Bioorg Med Chem, 2012 Quinols have been developed as a class of potential anti-cancer compounds. They are thought to act as double Michael acceptors, forming two covalent bonds to their target protein(s). Quinols have also been shown to have activity against the parasite Trypanosoma brucei, the causative organism of human African trypanosomiasis, but they demonstrated ...
Capes A +10 more
europepmc +4 more sources
Scalable Access to N‑Acylindole Linkages: Enabling the Synthesis of Antitrypanosomal Noncanonical Cyclic Peptides for Chagas Disease. [PDF]
Angew Chem Int Ed EnglA gram‐scale supply of bulbiferamide A, which features a rare N‐acylindole linkage and possesses potent inhibitory activity against Trypanosoma cruzi epimastigotes (IC50 = 4.1 µM)—the causative parasite of Chagas disease—was successfully achieved. Moreover, the cyclization strategy developed in this study facilitated the synthesis of noncanonical ...
Zhang J, Nakamura H.
europepmc +3 more sources
Anti-protozoal activity and metabolomic analyses of Cichorium intybus L. against Trypanosoma cruzi
International Journal for Parasitology: Drugs and Drug Resistance, 2022 Chagas disease, caused by the protozoa Trypanosoma cruzi, is a potentially life-threatening parasitic zoonosis infecting 6–7 million people worldwide, mainly in Latin America.
Miguel Peña-Espinoza +7 more
doaj +1 more source
Evaluation of the in vitro [PDF]
, 2015 Trypanosomiasis is a neglected tropical disease with complex clinical manifestations, tedious diagnosis, and difficult treatments. The drugs available for the treatment of this endemic disease are old, expensive, and associated with other problems ...
Lai, Daowan +13 more
core +1 more source
Molecules, 2017 Chagas disease or American trypanosomiasis is a worldwide public health problem. In this work, we evaluated 26 new propyl and isopropyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives as potential trypanocidal agents. Additionally, molecular docking
Karla Fabiola Chacón-Vargas +11 more
doaj +1 more source
Multiorgan Dysfunction Caused by Travel-associated African Trypanosomiasis
Emerging Infectious Diseases, 2012 We describe a case of multiorgan dysfunction secondary to Trypanosoma brucei rhodesiense infection acquired on safari in Zambia. This case was one of several recently reported to ProMED-mail in persons who had traveled to this region.
Lucy E. Cottle +8 more
doaj +1 more source
Differential Gel Electrophoresis (DIGE) Evaluation of Naphthoimidazoles Mode of Action: A Study in Trypanosoma cruzi Bloodstream Trypomastigotes. [PDF]
PLoS Neglected Tropical Diseases, 2016 BACKGROUND:The obligate intracellular protozoan Trypanosoma cruzi is the causative agent of Chagas disease, a neglected illness affecting millions of people in Latin America that recently entered non-endemic countries through immigration, as a ...
Giselle Villa Flor Brunoro +8 more
doaj +1 more source
Molecules, 2017 Chagas disease (CD) is a neglected disease caused by the parasite Trypanosoma cruzi, which affects underdeveloped countries. The current drugs of choice are nifurtimox and benznidazole, but both have severe adverse effects and less effectivity in chronic
Isidro Palos +7 more
doaj +1 more source
Marine Drugs, 2014 Chagas’ disease, a vector-transmitted infectious disease, is caused by the protozoa parasite Trypanosoma cruzi. Drugs that are currently available for the treatment of this disease are unsatisfactory, making the search for new chemotherapeutic agents a ...
Vânia Cristina Desoti +6 more
doaj +1 more source